Streetbeat News

Revenues

GTBIF

Green Thumb Industries (OTCQX:GTBIF) reported an 11% increase in Q1 2024 revenue to $276 million, with a GAAP net income of $31 million, marking a 240% year-over-year increase. Adjusted EBITDA rose to $91 million, and cash flow from operations increased by 12% to $84 million. The growth is attributed to expanded retail operations and consumer packaged goods sales, including 15 additional RISE Dispensaries and new adult-use sales in Maryland. The company also repurchased 1,067,000 shares for $13.6 million.

Portfolio Pulse from Maureen Meehan

May 08, 2024 | 9:22 pm

PETQ

PetIQ anticipates Q2 net sales to be between $325M-$335M, slightly below the estimated $335.976M, but has raised its FY24 forecast from $1.130B-$1.180B to $1.135B-$1.185B, surpassing the estimated $1.149B. The company also expects Q2 adjusted EBITDA of $34.0M-$36.0M and FY24 adjusted EBITDA of $112.0M-$118.0M.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:20 pm

LSF

Laird Superfood projects its FY24 net sales to be between $38M and $42M, indicating a growth rate of 11-23%.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:19 pm

TASK

TaskUs projects Q2 revenue to be between $230M-$232M, surpassing the estimated $227.02M, and forecasts FY24 revenue to be in the range of $925M-$950M, closely aligning with the estimated $927.86M.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:18 pm

STKL

SunOpta (NASDAQ:STKL) reported Q1 2024 earnings of $0.02 per share, missing the consensus estimate of $0.03. However, their sales of $182.848M exceeded the estimate of $168.397M, marking a 17.99% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:16 pm

ORA

Ormat Technologies has reaffirmed its revenue guidance for FY24, projecting revenues to be in the range of $860M-$910M, with estimates around $888.201M.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:15 pm

GRWG

GrowGeneration, a company specializing in hydroponic and organic gardening supplies, has reiterated its net sales outlook for 2024, projecting revenues to be in the range of $205 million to $215 million. This reaffirmation indicates the company's confidence in its growth trajectory and operational strategies moving forward.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:15 pm

AZEK

The AZEK Company has updated its Q3 revenue forecast to $385M-$400M, compared to a $390.11M estimate, and raised its FY24 revenue guidance to $1.407B-$1.438B, against a $1.42B estimate. The company also increased its fiscal 2024 net sales and Adjusted EBITDA outlook, expecting net sales between $385M to $400M and Adjusted EBITDA between $103M to $110M for Q3.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:14 pm

STE

STERIS projects FY25 revenue from continuing operations to grow by 6.5%-7.5% and forecasts adjusted EPS from continuing operations to be between $9.05 and $9.25, slightly below the estimated $9.33. Capital expenditures are expected to be around $360 million, with free cash flow projected at $700 million.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:13 pm

AMPH

Amphastar Pharma reported Q1 2024 adjusted EPS of $1.04, surpassing the $0.77 estimate, but its sales of $171.800M fell short of the $174.713M forecast. This represents a 22.70% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:11 pm